218 related articles for article (PubMed ID: 12831351)
1. Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections.
Blasi F; Tarsia P; Cosentini R; Cazzola M; Allegra L
Expert Opin Investig Drugs; 2003 Jul; 12(7):1165-77. PubMed ID: 12831351
[TBL] [Abstract][Full Text] [Related]
2. Highlights on the appropriate use of fluoroquinolones in respiratory tract infections.
Blasi F; Tarsia P; Aliberti S; Santus P; Allegra L
Pulm Pharmacol Ther; 2006; 19 Suppl 1():11-9. PubMed ID: 16310389
[TBL] [Abstract][Full Text] [Related]
3. A critical review of the fluoroquinolones: focus on respiratory infections.
Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
[TBL] [Abstract][Full Text] [Related]
4. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
Balfour JA; Lamb HM
Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103
[TBL] [Abstract][Full Text] [Related]
5. Multicenter evaluation of the efficacy and safety of gatifloxacin in Mexican adult outpatients with respiratory tract infections.
Casillas JL; Rico G; Rodríguez-Parga D; Mascareño A; Rangel-Frausto S
Adv Ther; 2000; 17(6):263-71. PubMed ID: 11317829
[TBL] [Abstract][Full Text] [Related]
6. Clinical perspectives on new antimicrobials: focus on fluoroquinolones.
Talan DA
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S64-71. PubMed ID: 11249831
[TBL] [Abstract][Full Text] [Related]
7. New antibiotics for community-acquired lower respiratory tract infections: improved activity at a cost?
Ball P
Int J Antimicrob Agents; 2000 Nov; 16(3):263-72. PubMed ID: 11091046
[TBL] [Abstract][Full Text] [Related]
8. [A new generation of fluoroquinolones--new possibilities for the treatment of respiratory community-acquired infections].
Iakovlev SV
Antibiot Khimioter; 2001; 46(6):38-42. PubMed ID: 11573324
[No Abstract] [Full Text] [Related]
9. What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections?
Momméja-Marin H; Carbon C
Drugs; 1999 Jun; 57(6):851-3. PubMed ID: 10400400
[TBL] [Abstract][Full Text] [Related]
10. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
Pfaller MA; Ehrhardt AF; Jones RN
Am J Med; 2001 Dec; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of the clinical efficacy and safety of injectable quinolones in the treatment of respiratory tract infections (discussion)].
Kohno S; Watanabe A; Mikasa K; Asano K
Jpn J Antibiot; 2003 Apr; 56(2):93-104. PubMed ID: 12825412
[No Abstract] [Full Text] [Related]
12. Fluoroquinolones in respiratory infections.
Klein NC
Semin Respir Infect; 1991 Sep; 6(3):131-5. PubMed ID: 1754733
[TBL] [Abstract][Full Text] [Related]
13. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.
Nightingale CH
Pharmacotherapy; 2000 Mar; 20(3):245-56. PubMed ID: 10730681
[TBL] [Abstract][Full Text] [Related]
14. [Use of new quinolones in respiratory infections].
Sanz Moreno J; Jiménez Rodríguez A
Rev Clin Esp; 2000 Dec; 200(12):682-4. PubMed ID: 11234474
[No Abstract] [Full Text] [Related]
15. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
Martin SJ; Jung R; Garvin CG
Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections.
Zhanel GG; Noreddin AM
Curr Opin Pharmacol; 2001 Oct; 1(5):459-63. PubMed ID: 11764770
[TBL] [Abstract][Full Text] [Related]
17. Gemifloxacin: survival of the fittest.
Mandell L
J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():33-7. PubMed ID: 10997597
[TBL] [Abstract][Full Text] [Related]
18. Sparfloxacin: a review.
Schentag JJ
Clin Ther; 2000 Apr; 22(4):372-87; discussion 371. PubMed ID: 10823360
[TBL] [Abstract][Full Text] [Related]
19. A review of clinical trials with fluoroquinolones with an emphasis on new agents.
Blondeau JM
Expert Opin Investig Drugs; 2000 Feb; 9(2):383-413. PubMed ID: 11060684
[TBL] [Abstract][Full Text] [Related]
20. Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features.
Blondeau JM; Hansen GT
Expert Opin Pharmacother; 2001 Feb; 2(2):317-35. PubMed ID: 11336589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
